The amount of injected ¹⁷⁷Lu-octreotate strongly influences biodistribution and dosimetry in C57BL/6N mice

Abstract

Background. ¹⁷⁷Lu-octreotate therapy has proven to give favorable results after treatment of patients with neuroendocrine tumors. Much focus has been on the binding and uptake of ¹⁷⁷Lu-octreotate in tumor tissue, but biodistribution properties in normal tissues is still not fully understood, and the effect of receptor saturation may be important. The aim of this study was to investigate the influence of the amount of ¹⁷⁷Lu-octreotate on the biodistribution of ¹⁷⁷Lu-octreotate in normal tissues in mice.

Material and methods. C57BL/6N female mice were intravenously injected with 0.1–150 MBq ¹⁷⁷Lu-octreotate (0.039 μg peptide/MBq). The mice were killed 0.25 h to 14 days after injection by cardiac puncture under anesthesia. Activity concentration was determined in blood, bone marrow, kidneys, liver, lungs, pancreas, and spleen, and mean absorbed doses were calculated.

Results. The activity concentration varied with time and amount of injected activity. At 4–8 h after injection, a local maximum in activity concentration was found for liver, lungs, pancreas, and spleen. With the exception for the lower injected activities (0.1–1 MBq), the overall highest uptake was found in the kidneys (%IA/g). Large variations were found and the activity concentration in kidneys was 11–23%IA/g at 4 h, and 0.22–1.9%IA/g at 7 days after injection. Furthermore, a clear reduction in activity concentration with increased injected activity was observed for lungs, pancreas and spleen.

Conclusion. The activity concentration in all tissues investigated was strongly influenced by the amount of ¹⁷⁷Lu-octreotate injected. Large differences in mean absorbed dose per unit injected activity were found between low (0.1–1 MBq, 0.0039–0.039 μg) and moderate amounts (5–45 MBq, 0.2–1.8 μg). Furthermore, the results clearly showed the need for better ways to estimate absorbed dose to bone marrow other than methods based on a single blood sample analysis. Since the absorbed dose to critical organs will limit the amount of ¹⁷⁷Lu-octreotate administered, these findings must be taken into consideration when optimizing this type of therapy.

Acknowledgments

The authors thank Lilian Karlsson and Ann Wikström for their skilled technical assistance. This study was supported by grants from the Swedish Research Council (grant no. 21073), the Swedish Cancer Society (grant no. 3427), BioCARE – a National Strategic Research Program at the University of Gothenburg, the Swedish Radiation Safety Authority, the King Gustav V Jubilee Clinic Cancer Research Foundation, the Sahlgrenska University Hospital Research Funds, the Assar Gabrielsson Cancer Research Foundation, the Lions Cancerfond Väst, and the Adlerbertska Research Foundation in Gothenburg, Sweden. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Supplementary material available online

Supplementary Figure 1 and Table I available online at http://informahealthcare.com/doi/abs/10.3109/0284186X.2015.1027001